In order for a biotechnology/product to infringe on a patent, it is sufficient that a single claim applies to the technology/product that is being monetized by the infringer. Receiving government money specifically to develop and manufacture such product like Moderna did in April could be interpreted as such monetization. More typically, however, it is the actual sale of pharmaceutical products that is viewed as an act of infringement.